tbuckley/cabot-search huggingface dataset:
Predicting Malignancy in Adnexal Tumors With FAPI PET/CT and FDG PET/CT
Authors: Janani Kantharooban Umachanger, Helle Damgaard Zacho, Camilla Sylvest, Anna Poulsgaard Frandsen, Morten Bentestuen
Journal: Clinical Nuclear Medicine (2024)

Abstract A 54-year-old woman presented with a 55 × 64-mm tumor in the ovary with high [ 18 F]FDG uptake on [ 18 F]FDG PET/CT highly suggestive of ovarian cancer. Prior to surgery, the patient underwent [ 68 Ga]-Ga- fibroblast activation protein inhibitor (FAPI)-46 PET/CT, which revealed low [ 68 Ga]-Ga-FAPI-46 tumor uptake. Histopathology revealed a borderline ovarian tumor, which has low malignant potential and a 10-year survival rate greater than 93%. High [ 18 F]FDG uptake is considered a fair predictor of malignancy in adnexal tumors. The present case demonstrates the potential superiority of [ 68 Ga]-Ga-FAPI-46 PET/CT over [ 18 F]-FDG PET/CT in differentiating malignant adnexal tumors from borderline ovarian tumors.
Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation
Authors: Oren Pasvolsky, Curtis Marcoux, Denái R. Milton, Babar Pal, Mark R. Tanner, Qaiser Bashir, Samer Srour, Jaehyun Lee, Neeraj Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Guilin Tang, Yosra Aljawai, Partow Kebriaei, Melody R. Becnel, Hans C. Lee, Krina K. Patel, Sheeba K. Thomas, Robert Z. Orlowski, Elizabeth J. Shpall, Richard E. Champlin, Muzaffar H. Qazilbash
Journal: Blood Cancer Journal (2024)

Autologous transplantation remains the standard of care for eligible multiple myeloma (MM) patients, yet optimal CD34
Teflon Granuloma With Active Inflammation: A Cause of Recurrent Trigeminal Neuralgia After Microvascular Decompression
Authors: Steven Herber, Richard S. Zimmerman, Alicia Chen, Ming Yang, Felipe Martinez
Journal: Clinical Nuclear Medicine (2024)

Abstract Trigeminal neuralgia (TN) is characterized by excruciating facial pain usually caused by neurovascular compression of the trigeminal nerve roots. TN can be treated medically or invasively. Microvascular decompression is the procedure of choice and usually results in complete symptom relief. During surgical decompression, Teflon can be placed between the offending vessel and the nerve root entry zone. In some cases, chronic Teflon-related inflammation can cause recurrent TN, which might lead to additional surgical intervention. We present imaging and histopathological correlation of a patient presenting with intractable recurrent TN approximately 2 years after microvascular decompression with Teflon implant.
Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen
Authors: Shai Shimony, Hari S. Raman, Yael Flamand, Julia Keating, Jonathan D. Paolino, Yannis K. Valtis, Andrew E. Place, Lewis B. Silverman, Stephen E. Sallan, Lynda M. Vrooman, Andrew M. Brunner, Donna S. Neuberg, Ilene Galinsky, Jacqueline S. Garcia, Eric S. Winer, Martha Wadleigh, Richard M. Stone, Jean M. Connors, Daniel J. DeAngelo, Marlise R. Luskin
Journal: Blood Cancer Journal (2024)

Abstract Asparaginase (ASP)-containing regimens for acute lymphoblastic leukemia (ALL) are associated with venous thromboembolism (VTE). We evaluated the prevalence, risk factors, role of prophylaxis and clinical impact of VTE among adolescents and young adult (AYA) patients (15–50 years) treated on Dana-Farber Cancer Institute (DFCI) ALL protocols. The 1- and 2-year cumulative incidence of VTE were 31.9% (95% CI: 27.0%, 36.9%) and 33.5% (95% CI: 28.5%, 38.5%) respectively, with most events occurring during ASP-based consolidation phase (68.6%). VTE was more frequent in patients with overweight/obese vs. normal BMI (39.2% vs. 29.0%, p = 0.048). In a 1-year landmark analysis, the 4-year overall survival was 91.5%, without difference between patients with vs. without VTE (93.8% vs. 90.0%, p = 0.93). Relapse and non-relapse mortality rates were also similar. Among patients treated at Dana-Farber/Harvard Cancer Center, cerebral sinus vein thrombosis occurred in 3.6% of patients (8.5% of VTE events) in comparison to pulmonary embolism (32.9%) and deep vein thromboses (58.6%, 24.4% line-associated). In a Cox regression model for VTE free-time, elevated BMI was associated with shorter VTE free-time (HR 1.94 [95% CI 1.13-3.35], p = 0.018), while low molecular weight heparin (LMWH) prophylaxis as time-varying covariate was not. In conclusion, we found that VTE was frequent in AYAs treated on DFCI ALL protocols but did not impact survival outcomes. Overweight/obese BMI increased risk for VTE.
A Rare Case of Tumor-Induced Osteomalacia Due to Mesenchymal Tumor at Foramen Magnum Diagnosed Preoperatively on 68Ga DOTATATE PET/CT
Authors: Chandra Mouli, Anurag Lila, Abhay Gondhane, Gaurav Malhotra, Tushar Bandgar
Journal: Clinical Nuclear Medicine (2024)

Abstract A 42-year-old man, a known case of FGF23-dependent hypophosphatemia, underwent 68 Ga- DOTATATE PET-CT, which showed a somatostatin receptor–expressing lesion in the left arch of foramen magnum that was correlated on MRI as a soft tissue lesion measuring 2.2 × 1.3 cm. It was excised and histopathologically confirmed as phosphaturic mesenchymal tumor. Postoperatively, patient improved clinically and recovered from hypophosphatemia completely. A distinct focal uptake in a 68 Ga- DOTATATE PET-CT in a patient with tumor-induced osteomalacia needs extensive workup and high degree of suspicion to rule out mesenchymal tumor at nonconventional location as seen in the present case.
Skeletal muscle from TBC1D4 p.Arg684Ter variant carriers is severely insulin resistant but exhibits normal metabolic responses during exercise
Authors: Jonas M. Kristensen, Rasmus Kjøbsted, Trine J. Larsen, Christian S. Carl, Janne R. Hingst, Johan Onslev, Jesper B. Birk, Anette Thorup, Dorte E. Steenberg, Jonas R. Knudsen, Nicolai S. Henriksen, Elise J. Needham, Jens F. Halling, Anders Gudiksen, Carsten F. Rundsten, Kristian E. Hanghøj, Sara E. Stinson, Birgitte Hoier, Camilla C. Hansen, Thomas E. Jensen, Ylva Hellsten, Henriette Pilegaard, Niels Grarup, Jesper Olesen, Sean J. Humphrey, David E. James, Michael L. Pedersen, Erik A. Richter, Torben Hansen, Marit E. Jørgensen, Jørgen F. P. Wojtaszewski
Journal: Nature Metabolism (2024)

In the Greenlandic Inuit population, 4% are homozygous carriers of a genetic nonsense TBC1D4 p.Arg684Ter variant leading to loss of the muscle-specific isoform of TBC1D4 and an approximately tenfold increased risk of type 2 diabetes1. Here we show the metabolic consequences of this variant in four female and four male homozygous carriers and matched controls. An extended glucose tolerance test reveals prolonged hyperglycaemia followed by reactive hypoglycaemia in the carriers. Whole-body glucose disposal is impaired during euglycaemic-hyperinsulinaemic clamp conditions and associates with severe insulin resistance in skeletal muscle only. Notably, a marked reduction in muscle glucose transporter GLUT4 and associated proteins is observed. While metabolic regulation during exercise remains normal, the insulin-sensitizing effect of a single exercise bout is compromised. Thus, loss of the muscle-specific isoform of TBC1D4 causes severe skeletal muscle insulin resistance without baseline hyperinsulinaemia. However, physical activity can ameliorate this condition. These observations offer avenues for personalized interventions and targeted preventive strategies. In Greenlandic Inuit, a TBC1D4 loss-of-function mutation increases type 2 diabetes risk by tenfold. Carriers show severe muscle insulin resistance, impaired glucose disposal and reduced muscle GLUT4, yet exercise mitigates these defects, offering potential for personalized lifestyle interventions.
Integration across biophysical scales identifies molecular and cellular correlates of person-to-person variability in human brain connectivity
Authors: Bernard Ng, Shinya Tasaki, Kelsey M. Greathouse, Courtney K. Walker, Ada Zhang, Sydney Covitz, Matt Cieslak, Audrey J. Weber, Ashley B. Adamson, Julia P. Andrade, Emily H. Poovey, Kendall A. Curtis, Hamad M. Muhammad, Jakob Seidlitz, Ted Satterthwaite, David A. Bennett, Nicholas T. Seyfried, Jacob Vogel, Chris Gaiteri, Jeremy H. Herskowitz
Journal: Nature Neuroscience (2024)

Brain connectivity arises from interactions across biophysical scales, ranging from molecular to cellular to anatomical to network level. To date, there has been little progress toward integrated analysis across these scales. To bridge this gap, from a unique cohort of 98 individuals, we collected antemortem neuroimaging and genetic data, as well as postmortem dendritic spine morphometric, proteomic and gene expression data from the superior frontal and inferior temporal gyri. Through the integration of the molecular and dendritic spine morphology data, we identified hundreds of proteins that explain interindividual differences in functional connectivity and structural covariation. These proteins are enriched for synaptic structures and functions, energy metabolism and RNA processing. By integrating data at the genetic, molecular, subcellular and tissue levels, we link specific biochemical changes at synapses to connectivity between brain regions. These results demonstrate the feasibility of integrating data from vastly different biophysical scales to provide a more comprehensive understanding of brain connectivity. Integration of postmortem molecular and dendritic spine morphological measurements enables the detection of microscale molecules associated with person-to-person variability in macroscale brain connectivity estimated from antemortem neuroimaging.
The dynamic evolution of lineage switch under CD19 CAR-T treatment in non-KMT2A rearranged B-ALL patients
Authors: Shaowei Qiu, Yihan Mei, Runxia Gu, Yu Liu, Manling Chen, Haiyan Xing, Kejing Tang, Zheng Tian, Qing Rao, Donglin Yang, Aiming Pang, Shuning Wei, Yujiao Jia, Huijun Wang, Sizhou Feng, Hui Wei, Ping Zhu, Min Wang, Ying Wang, Wenbing Liu, Jianxiang Wang
Journal: Leukemia (2024)
Circular RNA landscape in extracellular vesicles from human biofluids
Authors: Jingjing Zhao, Qiaojuan Li, Jia Hu, Hongwu Yu, Youmin Shen, Hongyan Lai, Qin Li, Hena Zhang, Yan Li, Zhuting Fang, Shenglin Huang
Journal: Genome Medicine (2024)

Circular RNAs (circRNAs) have emerged as a prominent class of covalently closed single-stranded RNA molecules that exhibit tissue-specific expression and potential as biomarkers in extracellular vesicles (EVs) derived from liquid biopsies. Still, their characteristics and applications in EVs remain to be unveiled. We performed a comprehensive analysis of EV-derived circRNAs (EV-circRNAs) using transcriptomics data obtained from 1082 human body fluids, including plasma, urine, cerebrospinal fluid (CSF), and bile. Our validation strategy utilized RT-qPCR and RNA immunoprecipitation assays, complemented by computational techniques for analyzing EV-circRNA features and RNA-binding protein interactions. We identified 136,327 EV-circRNAs from various human body fluids. Significantly, a considerable amount of circRNAs with a high back-splicing ratio are highly enriched in EVs compared to linear RNAs. Additionally, we discovered brain-specific circRNAs enriched in plasma EVs and cancer-associated EV-circRNAs linked to clinical outcomes. Moreover, we demonstrated that EV-circRNAs have the potential to serve as biomarkers for evaluating immunotherapy efficacy in non-small cell lung cancer (NSCLC). Importantly, we identified the involvement of RBPs, particularly YBX1, in the sorting mechanism of circRNAs into EVs. This study unveils the extensive repertoire of EV-circRNAs across human biofluids, offering insights into their potential as disease biomarkers and their mechanistic roles within EVs. The identification of specific circRNAs and the elucidation of RBP-mediated sorting mechanisms open new avenues for the clinical application of EV-circRNAs in disease diagnostics and therapeutics.
Personalized bioceramic grafts for craniomaxillofacial bone regeneration
Authors: Ana Beatriz G. de Carvalho, Maedeh Rahimnejad, Rodrigo L. M. S. Oliveira, Prabaha Sikder, Guilherme S. F. A. Saavedra, Sarit B. Bhaduri, Debby Gawlitta, Jos Malda, Darnell Kaigler, Eliandra S. Trichês, Marco C. Bottino
Journal: International Journal of Oral Science (2024)

Abstract The reconstruction of craniomaxillofacial bone defects remains clinically challenging. To date, autogenous grafts are considered the gold standard but present critical drawbacks. These shortcomings have driven recent research on craniomaxillofacial bone reconstruction to focus on synthetic grafts with distinct materials and fabrication techniques. Among the various fabrication methods, additive manufacturing (AM) has shown significant clinical potential. AM technologies build three-dimensional (3D) objects with personalized geometry customizable from a computer-aided design. These layer-by-layer 3D biomaterial structures can support bone formation by guiding cell migration/proliferation, osteogenesis, and angiogenesis. Additionally, these structures can be engineered to degrade concomitantly with the new bone tissue formation, making them ideal as synthetic grafts. This review delves into the key advances of bioceramic grafts/scaffolds obtained by 3D printing for personalized craniomaxillofacial bone reconstruction. In this regard, clinically relevant topics such as ceramic-based biomaterials, graft/scaffold characteristics (macro/micro-features), material extrusion-based 3D printing, and the step-by-step workflow to engineer personalized bioceramic grafts are discussed. Importantly, in vitro models are highlighted in conjunction with a thorough examination of the signaling pathways reported when investigating these bioceramics and their effect on cellular response/behavior. Lastly, we summarize the clinical potential and translation opportunities of personalized bioceramics for craniomaxillofacial bone regeneration.
Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathway
Authors: Shuxin Li, Jianyi Lv, Zhihui Li, Qiuyu Zhang, Jing Lu, Xueyun Huo, Meng Guo, Xin Liu, Changlong Li, Jinghui Wang, Hanping Shi, Li Deng, Zhenwen Chen, Xiaoyan Du
Journal: Molecular Cancer (2024)

Small cell lung cancer (SCLC) stands as one of the most lethal malignancies, characterized by a grim diagnosis and prognosis. The emergence of multi-drug resistance poses a significant hurdle to effective therapy. Although previous studies have implicated the long noncoding RNA LYPLAL1-DT in the tumorigenesis of SCLC, the precise role of the highly expressed LYPLAL1-DT in SCLC chemoresistance and the underlying mechanism remain inadequately understood.
Cell-autonomous IL6ST activation suppresses prostate cancer development via STAT3/ARF/p53-driven senescence and confers an immune-active tumor microenvironment
Authors: Christina Sternberg, Martin Raigel, Tanja Limberger, Karolína Trachtová, Michaela Schlederer, Desiree Lindner, Petra Kodajova, Jiaye Yang, Roman Ziegler, Jessica Kalla, Stefan Stoiber, Saptaswa Dey, Daniela Zwolanek, Heidi A. Neubauer, Monika Oberhuber, Torben Redmer, Václav Hejret, Boris Tichy, Martina Tomberger, Nora S. Harbusch, Jan Pencik, Simone Tangermann, Vojtech Bystry, Jenny L. Persson, Gerda Egger, Sarka Pospisilova, Robert Eferl, Peter Wolf, Felix Sternberg, Sandra Högler, Sabine Lagger, Stefan Rose-John, Lukas Kenner
Journal: Molecular Cancer (2024)

Prostate cancer ranks as the second most frequently diagnosed cancer in men worldwide. Recent research highlights the crucial roles IL6ST-mediated signaling pathways play in the development and progression of various cancers, particularly through hyperactivated STAT3 signaling. However, the molecular programs mediated by IL6ST/STAT3 in prostate cancer are poorly understood.
Folate-engineered chitosan nanoparticles: next-generation anticancer nanocarriers
Authors: Prashant Kesharwani, Kratika Halwai, Saurav Kumar Jha, Mohammed H. AL Mughram, Salem Salman Almujri, Waleed H. Almalki, Amirhossein Sahebkar
Journal: Molecular Cancer (2024)

Chitosan nanoparticles (NPs) are well-recognized as promising vehicles for delivering anticancer drugs due to their distinctive characteristics. They have the potential to enclose hydrophobic anticancer molecules, thereby enhancing their solubilities, permeabilities, and bioavailabilities; without the use of surfactant, i.e., through surfactant-free solubilization. This allows for higher drug concentrations at the tumor sites, prevents excessive toxicity imparted by surfactants, and could circumvent drug resistance. Moreover, biomedical engineers and formulation scientists can also fabricate chitosan NPs to slowly release anticancer agents. This keeps the drugs at the tumor site longer, makes therapy more effective, and lowers the frequency of dosing. Notably, some types of cancer cells (fallopian tube, epithelial tumors of the ovary, and primary peritoneum; lung, kidney, ependymal brain, uterus, breast, colon, and malignant pleural mesothelioma) have overexpression of folate receptors (FRs) on their outer surface, which lets folate-drug conjugate–incorporated NPs to target and kill them more effectively. Strikingly, there is evidence suggesting that the excessively produced FR&αgr (isoforms of the FR) stays consistent throughout treatment in ovarian and endometrial cancer, indicating resistance to conventional treatment; and in this regard, folate-anchored chitosan NPs can overcome it and improve the therapeutic outcomes. Interestingly, overly expressed FRs are present only in certain tumor types, which makes them a promising biomarker for predicting the effectiveness of FR-targeted therapy. On the other hand, the folate-modified chitosan NPs can also enhance the oral absorption of medicines, especially anticancer drugs, and pave the way for effective and long-term low-dose oral metronomic scheduling of poorly soluble and permeable drugs. In this review, we talked briefly about the techniques used to create, characterize, and tailor chitosan-based NPs; and delved deeper into the potential applications of folate-engineered chitosan NPs in treating various cancer types. Schematic illustration of target ligand-drug incorporated chitosan nanoparticles and its advantage in treating cancer. Figure created with BioRender.Com.
Alcohol and mortality in Mexico: prospective study of 150 000 adults
Authors: Eirini Trichia, Jesus Alegre-Díaz, Diego Aguilar-Ramirez, Raúl Ramirez-Reyes, Adrián Garcilazo-Ávila, Carlos González-Carballo, Fiona Bragg, Louisa Gnatiuc Friedrichs, William G Herrington, Lisa Holland, Jason Torres, Rachel Wade, Rory Collins, Richard Peto, Jaime Berumen, Roberto Tapia-Conyer, Pablo Kuri-Morales, Jonathan R Emberson
Journal: The Lancet Public Health (2024)
Contemporary epidemiology of hospitalised heart failure with reduced versus preserved ejection fraction in England: a retrospective, cohort study of whole-population electronic health records
Authors: Robert A Fletcher, Patrick Rockenschaub, Brendon L Neuen, Isabel Johanna Walter, Nathalie Conrad, Mehrdad A Mizani, Thomas Bolton, Claire A Lawson, Christopher Tomlinson, Stelios Boulitsakis Logothetis, Carmen Petitjean, Luigi Filippo Brizzi, Stephen Kaptoge, Elena Raffetti, Patrick A Calvert, Emanuele Di Angelantonio, Amitava Banerjee, Mamas A Mamas, Iain Squire, Spiros Denaxas, Theresa A McDonagh, Cathie Sudlow, Steffen E Petersen, Glenn M Chertow, Kamlesh Khunti, Johan Sundström, Clare Arnott, John G F Cleland, John Danesh, John J V McMurray, Muthiah Vaduganathan, Angela M Wood
Journal: The Lancet Public Health (2024)
City mobility patterns during the COVID-19 pandemic: analysis of a global natural experiment
Authors: Ruth F Hunter, Selin Akaraci, Ruoyu Wang, Rodrigo Reis, Pedro C Hallal, Sandy Pentland, Christopher Millett, Leandro Garcia, Jason Thompson, Kerry Nice, Belen Zapata-Diomedi, Esteban Moro
Journal: The Lancet Public Health (2024)

During the COVID-19 pandemic, changes were seen in city mobility patterns around the world, including in active transportation (walking, cycling, micromobility, and public transit use), creating a unique opportunity for global public health lessons and action. We aimed to analyse a global natural experiment exploring city mobility patterns during the pandemic and how they related to the implementation of COVID-19-related policies.
TLR Agonist Nano Immune Therapy Clears Peritoneal and Systemic Ovarian Cancer
Authors: Ben Marwedel, Henning De May, Lauren Anderson, Lorél Y. Medina, Ellie Kennedy, Erica Flores, John O'Rourke, Marian Olewine, Irina Lagutina, Lillian Fitzpatrick, Fred Shultz, Donna F. Kusewitt, Eric Bartee, Sarah Adams, Achraf Noureddine, Rita E. Serda
Journal: Advanced Healthcare Materials (2024)

Abstract Intraperitoneal (IP) administration of immunogenic mesoporous silica nanoparticles (iMSN) in a mouse model of metastatic ovarian cancer promotes the development of tumor‐specific CD8 + T cells and protective immunity. IP delivery of iMSN functionalized with the Toll‐like receptor (TLR) agonists polyethyleneimine (PEI), CpG oligonucleotide, and monophosphoryl lipid A (MPLA) stimulated rapid uptake by all peritoneal myeloid subsets. Myeloid cells quickly transported iMSN to milky spots and fat‐associated lymphoid clusters (FALCs) present in tumor‐burdened adipose tissues, leading to a reduction in suppressive T cells and an increase in activated memory T cells. Two doses of iMSN cleared or reduced ovarian and colorectal cancer and protected against future tumor engraftment. In contrast, subcutaneous (SC) and intravenous (IV) delivery of iMSN were without therapeutic effect in mice with peritoneal metastases, supporting the need for activation of regional immune cells. Remarkably, intraperitoneal delivery of iMSN cleared subcutaneously implanted ovarian cancer, supporting homing of antigen specific T cells to extraperitoneal tumor sites.
Unravelling the Reasons Behind Limited Response to Anti-PD Therapy in ATC: A Comprehensive Evaluation of Tumor-Infiltrating Immune Cells and Checkpoints
Authors: Monikongkona Boruah, Shipra Agarwal, Riyaz Ahmad Mir, Saumitra Dey Choudhury, Kapil Sikka, Sameer Rastogi, Nishikant Damle, Mehar C. Sharma
Journal: Endocrine Pathology (2024)
Estimated health benefits, costs, and cost-effectiveness of implementing WHO's sodium benchmarks for packaged foods in India: a modelling study
Authors: Kathy Trieu, Liping Huang, Leopold N Aminde, Linda Cobiac, Daisy H Coyle, Mary Njeri Wanjau, Sudhir Raj Thout, Bruce Neal, Jason H Y Wu, Lennert Veerman, Matti Marklund, Rachita Gupta
Journal: The Lancet Public Health (2024)
Metal-phenolic-network-coated gold nanoclusters for enhanced photothermal/chemodynamic/immunogenic cancer therapy
Authors: Tingyu Yang, Liqun Dai, Jie Liu, Yi Lu, Meng Pan, Lili Pan, Lin Ye, Liping Yuan, Xicheng Li, Zhongwu Bei, Zhiyong Qian
Journal: Bioactive Materials (2024)
Randomized Comparison of Novel Low-Dose Sirolimus-Eluting Biodegradable Polymer Stent vs Second-Generation DES
Authors: Robert W Yeh, Olivier F Bertrand, Ehtisham Mahmud, Emanuele Barbato, Batla Falah, Melek Ozgu Issever, Björn Redfors, Alexandra Popma, Michael Curtis, Niels van Royen, Jean-Francois Tanguay, Luc Janssens, William N Newman, Koen Teeuwen, James W Choi, Maurits T Dirksen, Akiko Maehara, Martin B Leon
Journal: Journal of the American College of Cardiology (2024)